Search

everythinglearnresearchcommunity

for

Search:↓

PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.

Selective androgen receptor modulators (SARMs) are a promising type of drug for various health conditions due to their targeted actions.

ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.

ROR-alpha may increase the growth of certain breast cancer cells by boosting aromatase, which could affect breast cancer prognosis.

RORA boosts autophagy in hair follicle stem cells, potentially aiding hair growth.

Bexxar is highly effective as a first treatment for non-Hodgkin's lymphoma, with most patients alive and many in remission after eight years.

Plerixafor may help treat pigmentation disorders by promoting skin repigmentation.

Testosterone reduces knee movement, while flutamide and finasteride increase it.

Strontium ranelate helps cartilage growth by blocking a specific cell pathway.

Ruxolitinib cream effectively treats skin conditions like atopic dermatitis and vitiligo with minimal side effects.

RORs may influence cashmere growth cycles.

Strontium ranelate helps cartilage growth by blocking a specific cell pathway.

Scientists successfully created and analyzed the structure of a part of the human androgen receptor with specific modulators and a peptide to understand how it binds differently in various tissues.

SARMs show promise but need more evidence to prove they're better than traditional androgens.

RU58841, a substance from France, can potentially block the effects of hormones that cause hair loss and excessive hair growth, performing better than a similar substance, cyproterone acetate.

RORA plays a key role in controlling seasonal hair molting by affecting hair follicle cell activity.

RU 58841 may treat acne, hair loss, and excessive hair growth.

The protein AtRXR3 limits root hair growth in Arabidopsis, affecting phosphorus uptake.

Scientists at the University of Michigan Medical School successfully created a special compound that can be used to improve imaging of prostate cancer.

The new delivery system improved raloxifene's skin absorption and effectiveness against cancer cells.

The PTH-CBD injection improved hair regrowth better than the daily ruxolitinib pill in mice.

CRTH2 antagonists might be useful for treating many conditions because they play a role in immune and inflammation responses.

Researchers developed new compounds that target the androgen receptor effectively with fewer side effects.

Scientists created iodinated arylhydantoins and arylthiohydantoins that could potentially be used for imaging prostate cancer. Some versions with specific side-chains showed high potential for this use.

Ruxolitinib can cause a delayed skin reaction on the nose.

ISX9 helps regrow hair by activating a specific cell signaling pathway.

Therapies targeting the androgen receptor are being developed to treat prostate cancer and improve bone and muscle health.

Two new compounds were found to build bone and muscle without affecting reproductive organs and skin oil glands.